Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Valero · SciRah

Researcher profile · Semantic Scholar

V. Valero

Share profile

V. Valero — researcher profile on SciRah

h-index: 12
Works: 69
Citations: 620

Most-cited papers

Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect.
B. Esmaeli, V. Valero, M. Ahmadi, D. Booser
2001Ophthalmology (Rochester, Minn.)143 citations
Semantic Scholar
Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers
T. Lester, Kelly K. Hunt, Khazi M. Nayeemuddin, Roland L. Bassett +7 more
2011Breast Cancer Research and Treatment62 citations Open access
Semantic Scholar
Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
B. Esmaeli, Sapna Amin, V. Valero, R. Adinin +4 more
2006Journal of Clinical Oncology57 citations
Semantic Scholar
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Edgardo Rivera, V. Valero, Laura Syrewicz, Z. Rahman +7 more
2001Journal of Clinical Oncology56 citations
Semantic Scholar
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
P. Tarantino, N. Tayob, G. Villacampa, C. Dang +46 more
2024Journal of Clinical Oncology47 citations Open access
Semantic Scholar
The impact of paravertebral block analgesia on breast cancer survival after surgery
J. Cata, M. Chávez-MacGregor, V. Valero, W. Black +6 more
2016Regional anesthesia and pain medicine39 citations
Semantic Scholar
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”
B. Lim, S. Seth, C. Yam, Lei Huo +27 more
2024Cell Reports Medicine26 citations Open access
Semantic Scholar
Multiparametric MRI–based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer
Rania M. M. Mohamed, B. Panthi, B. Adrada, M. Boge +25 more
2024Scientific Reports21 citations Open access
Semantic Scholar
Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer
Zhan Xu, David E Rauch, Rania M. M. Mohamed, Sanaz Pashapoor +27 more
2023Cancers16 citations Open access
Semantic Scholar
Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Zhan Xu, Zi-Jian Zhou, J. Son, Hao-Nan Feng +24 more
2025Cancers13 citations Open access
Semantic Scholar
Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
M. Gouda, Amrit S. Gonugunta, E. Dumbrava, T. Yap +11 more
2025Clinical Cancer Research13 citations
Semantic Scholar
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)
A. Waks, Emily L. Chen, N. Graham, A. M. Frey +29 more
2024JCO Oncology Practice12 citations Open access
Semantic Scholar
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.
D. Yardley, M. Untch, C. Barrios, A. Bardia +12 more
2024Journal of Clinical Oncology12 citations
Semantic Scholar
Advances in Targeting HER2 across Cancer Subtypes – A Pan-tumor Approach
T. Adesoye, E. Dumbrava, K. Raghav, Aysegul A. Sahin +9 more
2025Clinical Cancer Research11 citations Open access
Semantic Scholar
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer
B. Panthi, Rania M. M. Mohamed, B. Adrada, M. Boge +25 more
2023Frontiers in Oncology10 citations Open access
Semantic Scholar
NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.
V. Valero, G. Tang, P. Rastogi, C. Geyer +16 more
2025Journal of Clinical Oncology9 citations
Semantic Scholar
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
B. O'Brien, R. Murthy, D. Berry, Akshara Singareeka-Raghavendra +16 more
2024Journal of Clinical Oncology9 citations
Semantic Scholar
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
C. Yam, M. Patel, Holly Hill, Ryan Sun +35 more
2024Cancer Research Communications8 citations Open access
Semantic Scholar
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes
R. Basho, Li Zhao, J. White, Lei Huo +17 more
2024JCO Precision Oncology8 citations
Semantic Scholar
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
M. Benjapibal, A. Kudelka, A. Vasuratna, C. Edwards +4 more
1998Anti-Cancer Drugs8 citations
Semantic Scholar
Abstract PO3-20-06: TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer
P. Tarantino, S. Niman, A. Giordano, F. Nakhlis +12 more
2024Cancer Research7 citations
Semantic Scholar
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
T. Iwase, Evan N Cohen, Hui Gao, Angela Alexander +17 more
2024Clinical Cancer Research7 citations
Semantic Scholar
Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy
Benjamin C. Musall, David E Rauch, Rania M. M. Mohamed, B. Panthi +25 more
2024Journal of Magnetic Resonance Imaging6 citations Open access
Semantic Scholar
Assessment of the current medicare reimbursement system for breast cancer operations
Jeannie Shen, V. Valero, T. Buchholz, S. Singletary +6 more
2004Annals of Surgical Oncology6 citations
Semantic Scholar
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results
R. Murthy, B. O'Brien, Donald A. Berry, Akshara Singareeka-Raghavendra +18 more
2026Nature Cancer5 citations Open access
Semantic Scholar
Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial.
S. Yennurajalingam, V. Valero, Brandon G. Smalgo, M. Overman +10 more
2025The Journal of the National Comprehensive Cancer Network3 citations
Semantic Scholar
Abstract P1-01-28: Molecular Residual Disease Precedes Radiographic Confirmation of Recurrence in Patients with Stage III Inflammatory Breast Cancer
Jennifer H. Chen, S. Meas, R. Bassett, V. Sarli +6 more
2025Clinical Cancer Research2 citations
Semantic Scholar
A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)
B. Lim, A. Marx, M. Kai, A. Alexander +15 more
2025Therapeutic Advances in Medical Oncology2 citations Open access
Semantic Scholar
Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT
K. Ribi, Bernard F. Cole, Gini F. Fleming, B. Walley +25 more
2025Cancer2 citations
Semantic Scholar
Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.
Yao Wong, A. Raghavendra, C. Hatzis, J. P. Irizarry +7 more
20172 citations
Semantic Scholar
Abstract P1-08-13: 1000 Patient Prospective Inflammatory Breast Cancer (IBC) Registry Demonstrates Advances in Outcomes for IBC
Azadeh Nasrazadani, Rebecca S. Tidwell, M. Kai, R. Layman +8 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Abstract RF3-04: NRG-BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer
V. Valero, G. Tang, C. Geyer, P. Rastogi +13 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition
Azadeh Nasrazadani, Rebecca S. Tidwell, M. Kai, B. Lim +7 more
2025Breast Cancer Research1 citations Open access
Semantic Scholar
Abstract PO5-01-03: Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study
T. Iwase, S. Nithya, M. Kai, J. Willey +16 more
2024Cancer Research1 citations
Semantic Scholar
Abstract PS09-03: Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer
V. Valero, J. Mouabbi, Heather Alonzo, P. Pohlmann +12 more
2024Cancer Research1 citations
Semantic Scholar
Abstract PO5-06-02: Phase II Trial of Combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab and Eribulin (AE) in patients with metastatic inflammatory breast cancer (IBC): Clinical data of both cohorts
Angela Alexander, Hope Murphy, James Reuben, H. T. Carisa Le-Petross +16 more
2024Cancer Research1 citations
Semantic Scholar
Abstract PS1-07-23: Outcome After Locoregional Recurrences For Definitively Treated Non-Metastatic Inflammatory Breast Cancer
E. Onwubiko, M. Kai, M. Stauder, S. Sun +18 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS1-09-19: Real world outcomes of sacituzumab govitecan in hormone receptor-positive and triple-negative breast cancer: Impact of prior therapy
A. Raghavendra, Z. Wang, R. Bssett, S. Damodaran +7 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS5-02-03: Clinical Outcomes of Trastuzumab Emtansine (T-DM1) Following Trastuzumab Deruxtecan (T-DXd) in Metastatic Breast Cancer: A Single-Center Experience
V. Valero, Z. Wang, R. Bassett, R. Murthy +3 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS4-12-26: Neosaci-io: neoadjuvant sacituzumab govitecan (sg) + pembrolizumab (pb) in patients (pts) with early-stage tnbc experiencing suboptimal response to keynote-522
C. Yam, T. Iwase, B. Nelson, R. Bassett +28 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PD7-03: Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer
C. Yam, A. Radko, L. Huo, S. Akshara +46 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PD2-02: Stability of Estrogen receptor (ER), Progesterone receptor (PR), and Human epidermal growth factor receptor 2 (HER2) in Residual Invasive Tumor after Neoadjuvant Therapy in Inflammatory Breast Cancer
S. Krishnamurthy, R. Tidwell, M. Kai, L. Villareal +9 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial
V. Valero, P. Pohlmann, J. Mouabbi, Xue-Lin Huang +16 more
2026Nature Communications0 citations Open access
Semantic Scholar
Abstract PS4-07-22: Chemotherapy Decision Making and Outcomes in Very Early-Stage Triple Negative Breast Cancer
E. Lopez, A. Raghavendra, S. Pasyar, B. Lim +3 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS5-08-21: Prospective breast cancer clinical validation study of an ultrasensitive, tumor-informed, whole genome, circulating tumor DNA assay to detect molecular residual disease and predict recurrence of high-risk early breast cancer treated with standard (neo)adjuvant therapy; NSABP B-64
M. Basik, E. Diego, G. Tang, S. Puhalla +21 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Clinical outcomes of trastuzumab emtansine (T-DM1) following trastuzumab deruxtecan (T-DXd) in metastatic breast cancer: a single-center experience
A. Raghavendra, Zhong-Ya Wang, R. Bassett, R. Murthy +3 more
2026Breast Cancer Research0 citations Open access
Semantic Scholar
Abstract PS1-09-12: Trop2 expression and therapeutic opportunities in inflammatory breast cancer
S. Murray, A. Nasrazadani, C. Yam, A. Alexander +22 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS4-01-10: Characterizing CCR7 Gene Amplification and Protein Expression in Inflammatory and non-inflammatory Breast Cancer
S. Shivhare, C. Sanchez, R. Larson, L. Dobrolecki +12 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract P1-07-09: Development and validation of Residual tumor Burden calculator specific for Inflammatory breast carcinoma (IBC) to predict outcome (R-IBC)
S. Krishnamurthy, R. Bassett, Azadeh Nasrazadani, R. Layman +9 more
2025Clinical Cancer Research0 citations
Semantic Scholar
Abstract P2-08-08: Adjuvant Cyclin Dependent Kinase 4/6 Inhibition in Inflammatory Breast Cancer
Azadeh Nasrazadani, Rebecca S. Tidwell, M. Kai, Bora Lim +6 more
2025Clinical Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Layman×15
Invite
R. Layman — researcher profile on SciRah
W. Woodward×14
Invite
W. Woodward — researcher profile on SciRah
C. Yam×13
Invite
C. Yam — researcher profile on SciRah
D. Tripathy×10
Invite
D. Tripathy — researcher profile on SciRah

×10

Invite

S. Saleem — researcher profile on SciRah

Invite

Lei Huo — researcher profile on SciRah

Invite

J. White — researcher profile on SciRah

Invite

J. Litton — researcher profile on SciRah

Invite

B. Adrada — researcher profile on SciRah

Invite

R. Murthy — researcher profile on SciRah

R. Candelaria×7

Invite

R. Candelaria — researcher profile on SciRah

Invite

A. Korkut — researcher profile on SciRah